Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 150 percent decrease over losses of $(0.04) per share from the same period last year.
RBC Capital Downgrades Bank of Nova Scotia to Sector Perform, Lowers Price Target to C$83
RBC Capital analyst Darko Mihelic downgrades Bank of Nova Scotia (TSX:BNS) from Outperform to Sector Perform and lowers the price target from C$94 to C$83.
